跳至主要内容
临床试验/NCT03509662
NCT03509662已完成2 期

Early High-dose Vitamin C in Post-cardiac Arrest Syndrome

Amsterdam UMC, location VUmc1 个研究点 分布在 1 个国家目标入组 270 人开始时间: 2019年10月7日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
270
试验地点
1
主要终点
The delta (Δ) Sequential Organ Failure Assessment (SOFA) score

研究概览

简要总结

Only half of the patients suffering from cardiac arrest arrive at the hospital alive. Of these survivors, more than 50% will still die or remain severely disabled. During cardiac arrest ischemia causes damage to the vital organs, especially the brain. When with return of spontaneous circulation oxygen is re-offered to the ischemic organs, massive amounts of reactive oxygen species (ROS) are produced. These ROS can further increase the damage to the myocardium and brain (reperfusion injury). Vitamin C is the primary circulating antioxidant. It scavenges free radicals and reduces the production of ROS. In a recent study we demonstrated that vitamin C plasma levels are deficient in ~60% of the patients after cardiac arrest, probably due to massive consumption. Vitamin C deficiency reduces the protection against oxidative stress. Intravenous supplementation is needed to restore deficiency and the antioxidative effect of vitamin C is much more potent if it is administered in a supraphysiological dose (≥ 3 g per day). Its strong antioxidative effect may reduce damage to the circulation and to brain, heart and other organs. Beneficial effects of high dose i.v. vitamin C after cardiac arrest have been demonstrated in preclinical studies, but not in patients.

The investigators hypothesize that vitamin C can reduce organ damage, especially cerebral injury, if administered for a short period as a high i.v. dose during the very early phase of reperfusion after cardiac arrest.

Objectives:

  • To determine whether an early high dose i.v. vitamin C can improve organ function, especially neurological outcome, in patients after cardiac arrest
  • To explore the optimal dosing regimen for high dose i.v. vitamin C
  • To investigate in vitro the difference in effect of plasma obtained from post cardiac arrest patients treated with placebo, 3 gr/day or 10 gr/day vitamin C on endothelial cell viability and underlying oxidative pathways.

详细描述

Problem definition.

In Europe, each day more than 1000 patients suffer from cardiac arrest. Despite improvement of medical technologies mortality is still very high, around 75 - 80%. Of the patients who initially survive to Intensive Care Unit (ICU) admission, more than 50% still dies or remains severely disabled due to the post cardiac arrest syndrome (PCAS). Crucial in this syndrome is the overwhelming oxidative stress, which is caused by systemic ischemia/reperfusion injury and leads to destruction of endothelial function with cardiovascular failure and brain damage. Besides targeted temperature management, we have no effective therapy to improve prognosis. The levels of our primary circulating antioxidant, vitamin C, are markedly depressed after cardiac arrest. Early, high dose intravenous (iv) vitamin C administration can boost the body's antioxidant defence, and could be a new promising therapeutic intervention to improve clinical outcome by limiting oxidative damage.

Rationale high dose vitamin C.

Vitamin C administration is often wrongly considered as complementary or even alternative medicine, which does not do justice to the strong scientific base of the pleiotropic antioxidative effects of high-dose iv (not enteral!) vitamin C administration as demonstrated in multiple preclinical and clinical studies. With enteral supplementation maximally tolerated dosages cannot achieve plasma levels of > 250 µmol/l due to limited absorption. In critically ill patients, enteral supplementation even cannot restore deficiency due to the acutely increased requirements. Iv vitamin C administration generates much higher plasma levels, thus yielding more and more potent antioxidative effects. The underlying pathophysiological mechanisms are well elucidated. High plasma levels of vitamin C not only limit the generation of reactive oxygen species (ROS), repair other oxidized scavengers such as glutathione and modulate numerous enzyme reactions, but can also act as a direct radical scavenger. In addition, vitamin C maintains nitric oxide mediated endothelial integrity and vasomotor control. Furthermore, vitamin C is a cofactor in several biosynthetic pathways, such as collagen, catecholamines and peptide hormones. Deficiency will decrease there formation. Vitamin C can thereby recover endogenous vasopressor synthesis and improve wound healing.

Post cardiac arrest huge amounts of ROS are generated by various pathways. The main source of ROS are the mitochondria due to uncoupling of oxidative phosphorylation. In addition, ROS are produced by upregulated enzymes such as NADPH oxidase or during oxidation of catecholamines. When unopposed these ROS can damage virtually every biomolecule and cause severe endothelial dysfunction. This has been demonstrated in vitro: plasma derived from patients after cardiac arrest induced massive cell death of cultured endothelial cells due to pro-oxidant stress and deterioration of anti-oxidant defenses. Cell death was highest immediately after admission to the ICU.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • An out-of-hospital cardiac arrest with return of spontaneous circulation
  • Ventricular fibrillation or ventricular tachycardia as first registered cardiac rhythm
  • Glasgow Coma Scale (GCS)-score ≤8.

排除标准

  • Patients with pre-existent terminal renal insufficiency
  • Known glucose 6-phosphate dehydrogenase deficiency (risk of hemolysis)
  • History of urolithiasis, oxalate nephropathy or hemochromatosis
  • Treatment limitations.

研究组 & 干预措施

Placebo group

Placebo Comparator

Group 1 will be treated with placebos for 4 days. All patients will receive Thiamine 200 mg q 12 hourly for 4 days to limit the conversion of vitamin C to oxalate

干预措施: Thiamine (Drug)

Placebo group

Placebo Comparator

Group 1 will be treated with placebos for 4 days. All patients will receive Thiamine 200 mg q 12 hourly for 4 days to limit the conversion of vitamin C to oxalate

干预措施: Placebos (Drug)

Vitamin C - 3 gr/day

Active Comparator

Group 2 will be treated with 1.5 gr Vitamin C b.i.d. (3 gr/day) for 4 days. All patients will receive Thiamine 200 mg q 12 hourly for 4 days to limit the conversion of vitamin C to oxalate

干预措施: Vitamin C (Drug)

Vitamin C - 3 gr/day

Active Comparator

Group 2 will be treated with 1.5 gr Vitamin C b.i.d. (3 gr/day) for 4 days. All patients will receive Thiamine 200 mg q 12 hourly for 4 days to limit the conversion of vitamin C to oxalate

干预措施: Thiamine (Drug)

Vitamin C - 10 gr/day

Active Comparator

Group 3 will be treated with 5 gr Vitamin C b.i.d. (10 gr/day) for 4 days. All patients will receive Thiamine 200 mg q 12 hourly for 4 days to limit the conversion of vitamin C to oxalate

干预措施: Vitamin C (Drug)

Vitamin C - 10 gr/day

Active Comparator

Group 3 will be treated with 5 gr Vitamin C b.i.d. (10 gr/day) for 4 days. All patients will receive Thiamine 200 mg q 12 hourly for 4 days to limit the conversion of vitamin C to oxalate

干预措施: Thiamine (Drug)

结局指标

主要结局

The delta (Δ) Sequential Organ Failure Assessment (SOFA) score

时间窗: 96 hours

ΔSOFA score is defined as the difference between SOFA admission and SOFA at 96 hours (46). Death at 96-hours will be counted as the maximum SOFA score (24 points).

次要结局

  • Modified Rankin Scale(At 30 and 180 days)
  • HUI-3 questionnaire(At 30 and 180 days)
  • Hospital-stay(The total length of hospital-stay will be determined from the date of ICU admission until the patient is discharged from the hospital or the date of death from any cause assessed up to 1 year after the first day of admission.)
  • Troponin and CK-MB(Maximum day 1)
  • Maximal Glasgow Coma Score(At 96-h and after weaning of sedation)
  • Cerebral Performance Categories(At 30 and 180 days)
  • Neuron-specific enolase(At day 1, 2 and 3)
  • Ventilation time(Total ventilation time during ICU stay will be determined when the patient is discharged from the ICU or when the patient past away from any cause, assessed up to 1 year after the first day of admission.)
  • CAM-ICU score(Daily for 1 week)
  • Oxidation-reduction potential(Day 1, 3 and 5)
  • Intensive Care (IC)-stay(The total length of IC-stay will be determined from the date of ICU admission until the patient is discharged from the Intensive Care Unit or the date of death from any cause, assessed up to 1 year after the first day of admission.)
  • Duration of vasopressor support(When the patient is discharged from the Intensive Care or when the patient past away, the total duration of vasopressor support will be determined, assessed up to 1 year after the first day of admission.)
  • Lung injury score(Daily for 1 week)
  • F2-isoprostanes(Daily from day 1 to 7)
  • Medical Research Council score(Day 3, 5 and 7)
  • Renal function(Serum creatinine will be measured daily till discharge from the ICU, assessed up to 1 year after the first day of admission.)
  • extended Glasgow Outcome Scale(At 30 and 180 days)
  • Mortality(180-day)
  • Need of renal replacement therapy(Need of renal replacement therapy during hospital admission will be determined at hospital discharge, assessed up to 1 year after the first day of admission.)
  • ICDSC score(Daily for 1 week)
  • C-reactive protein(Daily for 1 week)
  • Antioxidant capacity(Day 1, 3 and 5)
  • Vitamin C plasma concentrations(Daily from day 1 to 5)

研究者

发起方
Amsterdam UMC, location VUmc
申办方类型
Other
责任方
Principal Investigator
主要研究者

Angelique Spoelstra-de Man

M.D., Ph.D.

Amsterdam UMC, location VUmc

研究点 (1)

Loading locations...

相似试验